Dhrubajyoti Bandyopadhyay i wsp. Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management. J Lipids. 2018 online (dostępny pełen tekst)
… with the new advancements in clinical medicine, it has now become possible to bring down the LDL levels to as low as 15 mg/dl using PCSK9 monoclonal antibodies alone or in combination with statins …
Many trials conducted in the past were successful in reducing the LDL levels well below the target with a consequent reduction in CV risk. Though there is ample evidence that low LDL does protect from residual CV risk, there have also been a few studies claiming an increasing number of adverse events with low and extremely low LDL levels. Nevertheless, we have to wait for the result of ongoing trials to have a conclusive answer on the long-term effect of lowering the current LDL goal.
Journal of Lipids 2018